Medivir AB (STO:MVIR) announced on Monday the publication of the phase II study of MIV-711 in patients with osteoarthritis in the journal, Annals of Internal Medicine (DOI: 10.7326/M19-0675).

The title of the article is 'Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis', author; P.G Conaghan et al. In the same issue there is an editorial by J.N Katz, MD, Msc, with the title, 'Structural Modification in Osteoarthritis: Dawn of a New Day', (DOI: 10.7326/M19-3809), where the study results are discussed.

In the article, Dr Katz mentions the significant effect on changes in bone and cartilage degradation after six months of treatment with MIV-711, the high quality of Medivir's study data, as well as the likely need for longer treatment time to enable significant effect on pain.

According to Medivir, it is pleased that its study with MIV-711 in osteoarthritis has been published in a highly reputable scientific journal and that an editorial in the same issue suggests that its study may point to a way forward for disease modifying medicines for osteoarthritis. Medivir hopes that this will increase the external interest for MIV-711 as we continue to search for a partner for the further development of MIV-711.

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.